Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00009555 · ClinicalTrials.gov registry record · Phase 4

Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal Fat

A Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 4
Development phase
86
Enrollment target

NCT00009555: Completed Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

NCT00009555 is a Phase 4 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 86 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00009555, a Phase 4 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 4
Development phase
86 participants
Enrollment target

Study Summary

The purpose of this study is to see if treatment with testosterone will reduce abdominal fat in HIV-positive men. Many HIV patients on antiretroviral therapy show an increase in abdominal fat. Studies have shown that treatment with testosterone may decrease abdominal fat. This study will determine if testosterone will reduce abdominal fat in HIV patients.

Interventions

  • DRUG Testosterone

Trial Details

FieldValue
Enrollment Target 86 participants
Est. Completion 2006-03
Phase Phase 4

What the finished NCT00009555 record still lists

NCT00009555 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).

The record links to 0 conditions, and to 1 intervention - of which Testosterone is the first listed.

NCT00009555 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00009555 about?

NCT00009555 is a clinical study titled "Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal Fat". The purpose of this study is to see if treatment with testosterone will reduce abdominal fat in HIV-positive men. Many HIV patients on antiretroviral therapy show an increase in abdominal fat. Studies have shown that treatment with testosterone may decrease abdominal fat. This study will determine ...

What is the current status of trial NCT00009555?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 86 participants. Estimated completion is 2006-03.

What interventions are being tested in trial NCT00009555?

The interventions under investigation include: Testosterone (DRUG).

Who is sponsoring clinical trial NCT00009555?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00009555's enrollment target sits among peer trials

86 926th of 2000 higher than 1,073 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01639508 · 86 participants · Phase 2

    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

  • NCT03519269 · 86 participants · NA

    Navio Robotic Versus Conventional Total Knee Arthroplasty

  • NCT04132999 · 86 participants · NA

    PAP for Children With DS and OSAS

  • NCT04545957 · 86 participants · NA

    Jump: MR Simulation For Radiation Therapy Master Protocol

Source: ClinicalTrials.gov NCT00009555, the US trial registry maintained by the National Library of Medicine. NCT00009555 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.